A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)

Annals of the Rheumatic Diseases

Volumn 73, Issue 1, 2014, Pages 69-74

  Burmester, Gerd R ^a,b   Rubbert Roth, Andrea ^c   Cantagrel, Alain ^d   Hall, Stephen ^e   Leszczynski, Piotr ^f   Feldman, Daniel ^g   Rangaraj, Madura J ^h   Roane, Georgia ⁱ   Ludivico, Charles ^j   Lu, Peng ^k   Rowell, Lucy ^l   Bao, Min ^m   Mysler, Eduardo F ⁿ  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e CABRINI INSTITUTE   (Australia)

^f POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^g FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^h Arthritis and Diabetes Clinic   (United States)

ⁱ Rheumatology Associates   (United States)

^j East Penn Rheumatology Associates   (United States)

^k HOFFMANN LA ROCHE INC   (United States)

^l ROCHE PRODUCTS LTD   (United Kingdom)

^m GENENTECH INC   (United States)

ⁿ Organizacion Medica de Investigación ^*  (Argentina)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TOCILIZUMAB;

ACR20 RESPONSE; ACR50 RESPONSE; ACR70 RESPONSE; ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERIAL ARTHRITIS; BRAIN TUMOR; BREAST CANCER; CONTROLLED STUDY; DAS28; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HYPERSENSITIVITY; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; NEUTROPENIA; NON INFERIORITY MARGIN; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA;

DISEASE ACTIVITY; DMARDS (BIOLOGIC); RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84889667445     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203523     Document Type: Article

References (10)

1. Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther 2012;91:30-43.
2. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29. (Pubitemid 44497760)
3. Ohta S, Tsuru T, Terao K. Optimal dose prediction by pharmacokinetic and biomarker response of subcutaneous tocilizumab treatment a Phase I/II study evaluating the safety, pharmacokinetics and clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2010;62:S1115.
4. Stubenrauch K, Wessels U, Birnboeck H, et al. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther 2010;32:1597-609.
5. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97. (Pubitemid 351392039)
6. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80.
7. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609-21.
8. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
9. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.
10. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16. (Pubitemid 38530193)